TransGenic Group Inc
TransGenic Group Inc operates in the retail sector, specifically in the department stores industry, generating revenue through the sale of consumer goods.
Business. TransGenic Group Inc (2342.T) is a department store retailer listed on the Tokyo Stock Exchange. The company operates within the Consumer Cyclicals sector, specifically focusing on the Department Stores industry. It generates revenue through product sales, with key performance indicators including same-store sales growth, traffic, and average ticket size. Specific details regarding operating segments and geographic mix are not available.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
TransGenic Group Inc (2342.T) is a department store retailer listed on the Tokyo Stock Exchange. The company operates within the Consumer Cyclicals sector, specifically focusing on the Department Stores industry. It generates revenue through product sales, with key performance indicators including same-store sales growth, traffic, and average ticket size. Specific details regarding operating segments and geographic mix are not available.
TransGenic Group Inc maintains a strong liquidity position with a current ratio of 2.69, indicating the company can cover its short-term liabilities more than two times over. The company holds JPY 2,478,229,000 in cash and equivalents, which is a significant portion of its total assets of JPY 9,810,999,000. However, the company reported negative operating cash flow of JPY -392,454,000, which may signal operational inefficiencies or capital investment pressures.
In terms of profitability, TransGenic Group Inc has a return on equity (ROE) of 0.72% and a return on assets (ROA) of 0.43%, both of which are below the typical thresholds for strong performance in the retail sector. The company's operating income of JPY 15,328,000 is relatively low compared to its revenue of JPY 3,340,453,000, suggesting that the company is not generating substantial profit from its core operations.
The company's revenue is primarily concentrated in its domestic market, with no significant international operations disclosed. This lack of geographic diversification may expose the company to regional economic fluctuations and regulatory changes. The company's revenue concentration in a single market could be a risk factor, especially in the context of the retail sector's sensitivity to consumer spending trends.
Looking at the company's growth trajectory, the most recent actual revenue of JPY 13,005,130,000 is significantly lower than the reported revenue of JPY 3,340,453,000, indicating a potential discrepancy or a shift in reporting periods. The company's capital expenditure of JPY -265,668,000 suggests ongoing investment in infrastructure or expansion, which could be a positive sign for future growth. However, the negative operating cash flow may limit the company's ability to fund these investments internally.
The risk assessment for TransGenic Group Inc indicates low liquidity and dilution risks, with no immediate filing-based flags detected. The company's debt-to-equity ratio of 0.39 is relatively low, suggesting a conservative capital structure. However, the negative operating cash flow and the need for capital expenditures may increase the company's reliance on external financing in the future.
Recent events, including the company's financial performance and capital structure, suggest a mixed outlook. The company's ability to maintain its liquidity position while investing in growth will be critical for its long-term success. The company's financial health and strategic direction will need to be closely monitored to assess its ability to navigate the competitive retail landscape.
- TransGenic Group Inc has a strong liquidity position with a current ratio of 2.69.
- The company's profitability metrics, including ROE and ROA, are below typical thresholds for the retail sector.
- Revenue is concentrated in the domestic market, which may expose the company to regional economic fluctuations.
- The company's capital expenditure suggests ongoing investment in growth, but negative operating cash flow may limit internal funding.
- Low liquidity and dilution risks are reported, with no immediate filing-based flags detected.
Bull / Bear case
Generated · model-assistedRevenue grew at a 4.2% CAGR over four years, demonstrating consistent top-line expansion despite recent volatility.
The company maintains a low debt-to-equity ratio of 0.39, indicating a conservative capital structure relative to peers.
Dilution and liquidity risks are assessed as low, suggesting stable shareholder value and adequate market trading conditions.
Net margin of 1.27% remains positive, showing the company retains some profitability despite operating losses in recent periods.
Gross profit remained above 2.1 billion JPY in FY2025, indicating underlying product or service margins are still intact.
Operating income turned negative at -616.7 million JPY in FY2025, reflecting a fundamental failure in core business operations.
The company faces high credit risk, raising concerns about its ability to meet financial obligations and service existing debt.
In focus — financials by report
Revenue ¥3.47B, −0,7% YoY; Operating income −1 656,5% YoY.
- ▍Revenue ¥3.47B, −0,7% YoY
- ▍Operating income −1 656,5% YoY
- ▍Net income +98,6% YoY
- ▍Net margin -0.0%
Revenue ¥3.03B, −11,7% YoY; Operating income +153,7% YoY.
- ▍Revenue ¥3.03B, −11,7% YoY
- ▍Operating income +153,7% YoY
- ▍Net income +103,1% YoY
- ▍Net margin 0.1%
Revenue ¥3.20B, +10,9% YoY; Operating income +121,0% YoY.
- ▍Revenue ¥3.20B, +10,9% YoY
- ▍Operating income +121,0% YoY
- ▍Net income +127,1% YoY
- ▍Net margin 0.8%
Revenue ¥3.20B, −4,3% YoY; Operating income −3 189,7% YoY.
- ▍Revenue ¥3.20B, −4,3% YoY
- ▍Operating income −3 189,7% YoY
- ▍Net income −1 981,8% YoY
- ▍Net margin -25.0%
Revenue ¥3.50B; Operating income ¥6.2M.
- ▍Revenue ¥3.50B
- ▍Operating income ¥6.2M
- ▍Net margin -3.1%
Revenue ¥3.43B; Operating income -¥40.8M.
- ▍Revenue ¥3.43B
- ▍Operating income -¥40.8M
- ▍Net margin -2.4%
Revenue ¥2.88B; Operating income -¥108.5M.
- ▍Revenue ¥2.88B
- ▍Operating income -¥108.5M
- ▍Net margin -3.4%
Revenue ¥3.34B; Operating income ¥15.3M.
- ▍Revenue ¥3.34B
- ▍Operating income ¥15.3M
- ▍Net margin 1.3%
Revenue ¥13.01B, −0,6% YoY; Operating income −2 363,3% YoY.
- ▍Revenue ¥13.01B, −0,6% YoY
- ▍Operating income −2 363,3% YoY
- ▍Net income −26 767,7% YoY
- ▍Free cash flow −450,4% YoY
- ▍Net margin -8.4%
Revenue ¥13.08B, +14,5% YoY; Operating income +104,6% YoY.
- ▍Revenue ¥13.08B, +14,5% YoY
- ▍Operating income +104,6% YoY
- ▍Net income +101,0% YoY
- ▍Free cash flow +70,6% YoY
- ▍Net margin 0.0%
Revenue ¥11.43B, −9,1% YoY; Operating income −145,6% YoY.
- ▍Revenue ¥11.43B, −9,1% YoY
- ▍Operating income −145,6% YoY
- ▍Net income −121,8% YoY
- ▍Free cash flow −144,1% YoY
- ▍Net margin -3.6%
Revenue ¥12.58B, +13,8% YoY; Operating income +94,8% YoY.
- ▍Revenue ¥12.58B, +13,8% YoY
- ▍Operating income +94,8% YoY
- ▍Net income +243,5% YoY
- ▍Free cash flow +132,0% YoY
- ▍Net margin 14.9%
Valuation TTM
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- TransGenic Group Inc Market data — financials · 2026-05-26
- TransGenic Group Inc Market data — analyst estimates · 2026-05-26